Blood sugar level

Human medicines European public assessment report (EPAR): Amglidia, glibenclamide, Date of authorisation: 24/05/2018, Revision: 8, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Liver, Medical Subject Headings, Diarrhea, Marketing, Diabetes, INN, Diabetic ketoacidosis, Allergy, ATC, International, Pancreas, Insulin, Disease, Language, Blood, Porphyrin, Mellitus, Glycated hemoglobin, Mouth, Blood sugar level, Infant, Abdominal pain, Porphyria, KATP, European Medicines Agency, ATP, Tablet, Chronic pain, Select, Cell, Patient, Time, Anatomy, Medicine, IIA, Neonatal diabetes, Hypoglycemia, Life, Medical device

Human medicines European public assessment report (EPAR): Amglidia, glibenclamide, Date of authorisation: 24/05/2018, Revision: 8, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Amglidia, glibenclamide, Date of authorisation: 24/05/2018, Revision: 8, Status: Authorised

American Diabetes Association to Highlight Innovations in Diabetes Technology for Glucose Management and Diabetic Eye Condition

Retrieved on: 
Saturday, June 24, 2023
CGM, St. Vincent's Hospital, AID, Insulin, Risk, Synergism, University, Diabetes, Glucose, Algorithm, Quality of life, PDT, Saint Vincent, Diabetic retinopathy, Feasibility, Doctor of Philosophy, Associate, Movement, Harvard Medical School, UWF, HIV disease progression rates, Blood sugar level, Machine learning, Cannula, Physician, Patient, American Diabetes Association, Artificial intelligence, Hospital, AI, Joslin Diabetes Center, ADA, IPT, Medical device, Pharmaceutical industry, Ophthalmology, MD, Telehealth, Endocrinology

SAN DIEGO, June 23, 2023 /PRNewswire/ -- Today, findings from two studies showcase groundbreaking technology and the latest diabetes developments related to glucose control and diabetic retinopathy. Both studies were presented as late-breaking posters at the 83rd Scientific Sessions held by the American Diabetes Association® (ADA) in San Diego, CA.

Key Points: 
  • Both studies were presented as late-breaking posters at the 83rd Scientific Sessions held by the American Diabetes Association® (ADA) in San Diego, CA.
  • "We have seen many advancements over the years in the technology available to help manage and treat diabetes.
  • "We are excited that novel technology is at the forefront of this year's Scientific Sessions as we highlight the incredible developments that can help transform diabetes care."
  • SynerGTM is a dual-function glucose sensing-insulin delivery device developed by Pacific Diabetes Technologies that simplifies diabetes management.

Continuous Glucose Monitoring Fosters Blood Glucose Meters Industry Growth - Grand View Research, Inc.

Retrieved on: 
Wednesday, February 8, 2023
Benchmarking, CGM, Himawari (satellites), Traction, Insulin, Pan American Health Organization, Dexcom, Diagnosis, Innovation, Blood, POCT, Hypoglycemia, Diabetes, Blood sugar level, Red Data Book of the Russian Federation, POC, CDC, Intelligence, USD, Continuous glucose monitor, Disease, SAN, R, Self-management, COVID-19, PAHO, Abbott, Medical device, Retail, Pharmaceutical industry

An unprecedented rise in the diabetic population has furthered the demand for technologies monitoring blood glucose.

Key Points: 
  • An unprecedented rise in the diabetic population has furthered the demand for technologies monitoring blood glucose.
  • Blood glucose monitoring devices have witnessed increased traction across developing and developed countries, mainly due to the need to stay on track with blood sugar goals.
  • The growth trajectory is primarily attributed to the trend for continuous glucose monitoring (CGM) technologies to track blood sugar levels.
  • Blood glucose meters manufacturers and suppliers are expected to cash in on the prevailing growth potentials to expand their penetration across yet-to-be-penetrated areas.

Continuous Glucose Monitoring Fosters Blood Glucose Meters Industry Growth - Grand View Research, Inc.

Retrieved on: 
Wednesday, February 8, 2023
Benchmarking, CGM, Himawari (satellites), Traction, Insulin, Pan American Health Organization, Dexcom, Diagnosis, Innovation, Blood, POCT, Hypoglycemia, Diabetes, Blood sugar level, Red Data Book of the Russian Federation, POC, CDC, Intelligence, USD, Continuous glucose monitor, Disease, SAN, R, Self-management, COVID-19, PAHO, Abbott, Medical device, Retail, Pharmaceutical industry

An unprecedented rise in the diabetic population has furthered the demand for technologies monitoring blood glucose.

Key Points: 
  • An unprecedented rise in the diabetic population has furthered the demand for technologies monitoring blood glucose.
  • Blood glucose monitoring devices have witnessed increased traction across developing and developed countries, mainly due to the need to stay on track with blood sugar goals.
  • The growth trajectory is primarily attributed to the trend for continuous glucose monitoring (CGM) technologies to track blood sugar levels.
  • Blood glucose meters manufacturers and suppliers are expected to cash in on the prevailing growth potentials to expand their penetration across yet-to-be-penetrated areas.

Ontario Announces Public Coverage for the Dexcom G6 Continuous Glucose Monitoring System under the Assistive Devices Program

Retrieved on: 
Monday, March 7, 2022
Biotechnology, Diabetes, Health, Medical Devices, People, Sunnybrook Health Sciences Centre, Blood, Blood sugar level, COVID, Patient, Conditional sentence, CGM, JDRF, Multimedia, G6, Senior, COVID 19, Hypoglycemia, CEO, Glucose, Parent, Caregiver, Technology, First Nations, General manager, DXCM, Incidence, Skin, NASDAQ, ADP, Health insurance, Medical device, Phosphorus, Diabetes, Dexcom

View the full release here: https://www.businesswire.com/news/home/20220307005198/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220307005198/en/
    The Dexcom G6 CGM System will be covered through Ontarios Assistive Devices Program for people living with type 1 diabetes who are over 2 years of age and meet coverage criteria.
  • (Photo: Business Wire)
    Were pleased to be teaming up with the Ontario government to bring the Dexcom G6 CGM System to more Ontarians living with diabetes.
  • The Dexcom G6 is a life-changing technology for people with diabetes that also brings significant value to the Ontario healthcare system.
  • Ontario joins six other provinces or territories, most recently Alberta, offering public coverage of CGM systems under provincial health plans.

Dexcom G6 Continuous Glucose Monitoring System Now Covered in Alberta for Children and Youth Living With Diabetes

Retrieved on: 
Thursday, February 3, 2022
Public Policy, Government, Healthcare Reform, Medical Devices, Health, Diabetes, Biotechnology, People, Insulin, Patient, Parent, Blood, NASDAQ, A1C, Glucose, Blood sugar level, DXCM, CGM, General manager, G6, Hypoglycemia, First Nations, Â, Alberta Health Services, Incidence, Senior, Quality of life, Multimedia, Caregiver, Medical device, Health insurance, Dexcom, Diabetes

With expanded public coverage for CGM, more children and youth can access this standard of care technology, helping them manage their diabetes.

Key Points: 
  • With expanded public coverage for CGM, more children and youth can access this standard of care technology, helping them manage their diabetes.
  • We applaud the Alberta government for recognizing the value of real-time CGM and supporting access for its residents living with diabetes.
  • Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems.
  • Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial.

New Study Examines the Benefits of Eating Almonds on Blood Sugar and Daily Calorie Intake

Retrieved on: 
Thursday, November 11, 2021
Pinterest, University, Adoption, Industry, Lunch, Leadership, Blood sugar level, Degenerative disease, Farmer, Ageing, Appetite, Energy, United States Department of Agriculture, International Journal of Environmental Research and Public Health, Instagram, Snack, Federal, Twitter, Eating, Popular, Death, University of Otago, Weight loss, Alex Chisholm, Risk, Fast food

Both snacks accounted for 10% of total calorie intake, so in some cases, the amount of snack eaten was higher.

Key Points: 
  • Both snacks accounted for 10% of total calorie intake, so in some cases, the amount of snack eaten was higher.
  • Blood glucose and appetite ratings were measured at baseline and at 15 or 30-minute intervals after they finished eating.
  • Results showed that the blood sugar response was lower among participants after eating the almond snack versus the biscuit snack.
  • "Also, our study showed that almonds tempered the post-snack blood sugar response.

Blood Glucose Meters Global Market Report 2021 Featuring Abbott, Roche, Medtronics, Ascensia and Dexcom - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 1, 2021
Health, Diabetes, Blood sugar level, Blood, Product, International Diabetes Federation, Diabetes, Prevalence, Awareness, Country, Patient, Hypoglycemia, Application, FDA, COVID-19, Obesity, IDF, Medical device, Coal

The "Blood Glucose Meters Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Blood Glucose Meters Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the blood glucose meters market are Abbott, Roche, Medtronics, Ascensia and Dexcom.
  • Global Blood Glucose Meters Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
    7.2.
  • Global Blood Glucose Meters Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Global Blood Glucose Monitoring Market Report 2021-2025 - Market is Expected to Increase at a CAGR of 13.8% - ResearchAndMarkets.com

Retrieved on: 
Friday, July 30, 2021
Diabetes, Health, Medical devices, Medicine, Branches of biology, Diabetes, Clinical medicine, Medical monitoring, Continuous glucose monitor, Blood sugar level, Glucose, Blood glucose monitoring, Diabetes management

The "Diabetes Management: Blood Glucose Monitoring Devices Market (2021)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Diabetes Management: Blood Glucose Monitoring Devices Market (2021)" report has been added to ResearchAndMarkets.com's offering.
  • The burgeoning global blood glucose monitoring market is expected to increase at a healthy CAGR of 13.8%, from nearly $9.1bn in 2019, $9.8bn in 2020, to an estimated $19.7bn in 2025.
  • The blood glucose monitoring devices market includes: conventional handheld blood glucose meters (BGMs) that require frequent fingersticks, and new, sensor-based continuous glucose monitoring systems (CGMs) typically worn the upper arm or abdomen that conveniently monitor blood glucose 24/7, as well as lucrative supplies and software/accessories.
  • This comprehensive medical market and technology report provides:
    In-depth market and competitive analyses (market drivers/limiters, 6-year market forecasts by segment and region, 2019 and 2020 global/regional market share)

Global Diabetes Diagnostics Market Trajectory & Analytics Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 20, 2021
Health, Diabetes, Diabetes, Organ systems, Clinical medicine, Health, Blood sugar level, Blood glucose monitoring

The "Diabetes Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Diabetes Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Blood glucose test strips are small disposable strips of plastic that enable people with diabetes to measure and monitor their blood sugar levels at home.
  • The U.S. Market is Estimated at $10.8 Billion, While China is Forecast to Reach $5.2 Billion by 2026
    The Diabetes Diagnostics market in the U.S. is estimated at US$10.8 Billion in the year 2021.
  • Asia-Pacific represents a rapidly expanding market for diabetes diagnostics.